The cytokine IL1R1 appears incorrectly throughout the article. The correct cytokine name should be IL1RN, and the authors have updated the third paragraph of the Discussion section. The corrected paragraph is as follows:
The cytokine IL1R1 appears incorrectly throughout the article. The correct cytokine name should be IL1RN, and the authors have updated the third paragraph of the Discussion section. The corrected paragraph is as follows:
We found that CD101 risk variants are associated with lower plasma IL-1RN (interleukin-1 receptor antagonist protein) levels in HIV-1 uninfected persons, but not with altered HIV-1 RNA set point in HIV-1 seroconverters. This suggests that these variants have systemic immunological effects in the HIV-1 seronegative partner while not directly altering HIV-1 replication. IL-1RN antagonizes the pro-inflammatory effect of IL-1 by blocking IL-1 binding to its receptors. (Palomo, et al.) Recent studies in a mouse IL-1rn -/model indicate that excess IL-1 signaling may inhibit Treg and enhance Th17 differentiation [54] . However, it is unclear at this point where in the IL-1 pathway variants in CD101, specifically those identified in CD101 Ig-like domains, might impact either IL-1 or IL-1RN levels. If CD101 Ig-like variants primarily act at the level of reducing release of IL-1RN, this could leave circulating IL-1 unantagonized and therefore increase levels of Th17-associated peripheral inflammation. Alternatively, CD101 Ig-like variants may act directly to reduce IL-1 release; which may, in turn, result in a homeostatic reduction in IL-1RN levels. While efforts proceed to better understand the mechanism by which Ig-like variants alter CD101 function, our results suggest that development of methods to target CD101 activity could provide a novel approach to host-directed, HIV-1 prevention.
Additionally, the authors have added a reference in the second sentence of the corrected paragraph. The reference is: Palomo J, Dietrich D, Martin P, Palmer G, Gabay C. The interleukin (IL)-1 cytokine family-Balance between agonists and antagonists in inflammatory diseases. Cytokine 2015; 76(1): [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] In S8 Fig, the 
